[Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].
Remission rates of 30-50% can be obtained using different cytostatic combinations in second line therapy of metastatic breast cancer. The combination of adriamycin and vincristin with cytostasan revealed a remission rate of 50% in 62 CMF-pretreated patients. Considerable toxic side effects led to a dose reduction of cytostasan and adriamycine in 43 patients without clinical efficacy loss. The long remission periods of the total responders (8-23 months) were remarkable. Both, 3 patients with bone +/- soft tissue metastasis and 4 patients with visceral metastasis benefited from a clinical total remission. The remission rates indicated no significant differences between the group of patients with soft tissue +/- bone metastasis (47.3%) and that with a predominantly visceral metastasis (50%). The CyAV-combination with a low dosage provides an effective therapeutical scheme with acceptable side effects for CMF-pretreated patients with breast cancer.
Brockmann
B
B
Klinik und Poliklinik für Onkologie, Bereiches Medizin Charité, Humboldt-Universität zu Berlin.
Geschke
E
E
Schmidt
U M
UM
Ebeling
K
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan, Adriamycin und Vincristin als "Second line"-Therapie beim metastasierten Mammakarzinom.